Posters

Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour

Frances Brightman, Eric Fernandez, David Orrell, Christophe Chassagnole

Modelling and translating head and neck radiation therapy on all three levels: in vitro, in vivo and clinical

Éric Fernandez, Frances Brightman, David Orrell, Christophe Chassagnole

Modeling Synergistic Anti-PD-1/PD-L1 Immunotherapy Combinations with the Virtual Tumour

Frances Brightman, Eric Fernandez, David Orrell, Christophe Chassagnole

EasyAP: a Web-Based Simulation and Analysis Tool for High-Throughput Ion-Channel Screening Data

Eric Fernandez, Hitesh Mistry, Frances Brightman, David Orrell, Jonathan Swinton and Christophe Chassagnole

Virtual Tumour Clinical development, part II: translational modelling of vemurafenib, selumetinib and docetaxel in metastatic melanoma

Hitesh Mistry, Eric Fernandez, Frances Brightman, David Orrell, Mark Middleton, Linda Collins, Avinash Gupta, Christophe Chassagnole

Virtual Tumour Clinical development, part I: translational modelling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant prostate cancer

Frances Brightman, Hitesh Mistry, Eric Fernandez, David Orrell, William L. Dahut, William D. Figg, Sr., Wilfried D. Stein, Christophe Chassagnole

Reducing animal experiments with the Virtual Tumour

Eric Fernandez, Frances Brightman, Hitesh Mistry, David Orrell and Christophe Chassagnole

drugCARD: a database of anti-cancer treatment regimens and drug combinations

Eric Fernandez, Jianxiong Pang, Chris Snell, Cheryl Turner, Cathy Derow, Frances Brightman, Christophe Chassagnole and Robert Jackson

Virtual Tumour Clinical: Literature Example

Hitesh Mistry, Frances Brightman, Eric Fernandez, David Orrell, Christophe Chassagnole

Predicting Torsades de Pointes (TdeP) risk from data generated via highthroughput screening

Hitesh Mistry, Frances Brightman, Eric Fernandez, David Orrell, Jonathan Swinton, Christophe Chassagnole

The application of three-dimensional cell cultures in combination with the Virtual Tumor™ for designing optimal drug dosing schedules

Frances Brightman, Eric Fernandez, David Orrell, David Fell, Christophe Chassagnole

Modeling the sequence-sensitive gemcitabine-docetaxel combination using the Virtual Tumor

Eric Fernandez, David Orrell, Caroline Mignard, Zina Koob, Damien France, Nicolas Hoffmann, Francis Bichat, David Fell, Christophe Chassagnole

Predicting the effect of combination schedules on xenograft tumor using the Virtual Tumor

David Orrell, Eric Fernandez, Damien Cronier, Lawrence M. Gelbert, David A. Fell, Dinesh De Alwis and Christophe Chassagnole

Computer modelling of Nocodazole exposure on cell cultures in vitro

E Fernandez, G Johnson, D Orrell, C Snell, DA Fell, SH Doak and C Chassagnole

Chronotherapy: Seliciclib dosing schedules determined using a detailed computational cancer model

AR Hardy, E Fernandez, C Snell, D Orrell, DA Fell and C Chassagnole

Systems biology analysis of CYC116, a novel aurora kinase inhibitor

C Chassagnole, E Fernandez, F Scaërou, C Snell, D Zheleva, DM Glover, RC Jackson, DA Fell

Optimal cancer chronotherapeutic schedules of Seliciclib revealed by a systems biology approach

E Fernandez, A Hardy, D Orrell, L Ramsell, DA Fell and C Chassagnole

Modelling DNA Damage-Induced Apoptosis

A R Hardy, D Orrell, C M Snell, C Chassagnole, G Morris and D A Fell

Virtual Tumour Modelling The Effect of Aurora Kinase Inhibitors on the Cell Cycle

C Chassagnole, C M Snell, A R Hardy, A Finney, E Fernandez and D A Fell